Pharmaceutical companies set off a "cooperation tide", and the trend of leading companies to form a group is obvious

[Pharmaceutical Network Market Analysis] Affected by a series of policies such as medical insurance cost control, in recent years, major pharmaceutical companies are adjusting their strategies and divesting their marketing subsidiaries; Pipeline drug companies have also divested their pharmaceutical assets to stop losses
.

It is worth noting that at the same time, a large number of pharmaceutical companies are accelerating their formation
.

Since 2022, strategic cooperation has been reached very frequently among pharmaceutical companies, and news of cooperation has been reported by many pharmaceutical companies since April
.

For example, China Resources Double Crane recently signed a strategic cooperation agreement with Shenzhen Hanyu Pharmaceutical Co.
, Ltd.
(hereinafter referred to as: Hanyu Pharmaceutical)
.

According to the agreement, both parties will list each other as important long-term partners
.

In the cooperation, the marketing channels and customer resources of China Resources Shuanghe's advantageous regions will be combined with the advantageous product pipeline of Hanyu Pharmaceutical to fully expand the market, carry out product market expansion, product sales and academic promotion, and jointly build a multi-field, multi-product, The multi-dimensional cooperation model promotes the common development of the business of both parties
.

 　　On April 18, Aide Bio announced that the company signed two cooperation agreements with AstraZeneca
.

First, the company will work with AstraZeneca to promote the company's self-developed companion diagnostic products for the registration of companion diagnostics for prostate cancer patients with homologous recombination repair (HRR) gene mutations in China, the European Union and Japan; second, the company Will work with AstraZeneca to advance another companion diagnostic product independently developed by the company for the registration of companion diagnostics for breast cancer patients with BRCA mutations in the European region
.

 　　In mid-April, Nhwa Pharmaceutical and Shenshi Technology reached a strategic cooperation agreement.
The two parties jointly promoted Nhwa Pharmaceutical's research and development of small molecule innovative drugs in the central nervous system
.

At the same time, the two parties will further explore the advantages of cooperation, combine AI technology and innovative molecular research and development more widely, and accelerate and expand the research and development process and innovation dimension of drugs in the central nervous system
.

Shenshi Technology said that this cooperation will deeply integrate the computing paradigm based on 'AI + molecular simulation' into the actual cooperative research and development project, and jointly create a research and development model of 'computational design-experimental verification', looking forward to accelerating new drugs in the central nervous system.
Development brings more new results
.

 　　On April 7, Genting Xinyao announced that the company and China Resources Pharma signed a memorandum of cooperation to establish an independent company focused on the discovery, development and commercialization of mRNA vaccines
.

Genting Xinyao said that through cooperation with China Resources Pharma in the fields of registration and commercialization, it will gain advantages for the further development of mRNA company and promote the development progress of Genting Xinyao's best-in-class mRNA vaccine candidates in China
.

 　　In fact, the "marriage" of cooperation between pharmaceutical companies is the norm
.

But it is worth noting that this year, this situation is becoming more and more frequent
.

For example, there are more and more phenomena such as local pharmaceutical companies pre-innovative pharmaceutical companies, innovative pharmaceutical companies and multinational pharmaceutical companies, and cooperation between large and small companies, and the amount of cooperation involved is also increasing.
, testing and many other fields
.

 　　Industry analysts believe that in order to accelerate the development and commercialization of innovative drugs, cooperation between pharmaceutical companies will become more frequent in the future
.

And the more leading companies, the more they like to join forces
.

 　　Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.